Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
Viromed Medical AG: A reportable insider transaction was published on 6th June 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 6th June 2025,
The Insider Transaction was made by Perbandt, Uwe 
. The transaction toke place on 6th June 2025. . The aggregated volume was 1.000.000,00 EUR, based on an average price of 4,00 EUR. The nature of the Investment was Sell.
Allianz SE: A reportable insider transaction was published on 19th May 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 19th May 2025,
The Insider Transaction was made by Wagner, Renate . The transaction toke place on 12th May 2025. . The aggregated volume was 50.914,81 EUR, based on an average price of 358,56 EUR. The nature of the Investment was not specified.
Viromed Medical AG: A reportable insider transaction was published on 23rd April 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 23rd April 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 17th April 2025. . The aggregated volume was 440.000,00 EUR, based on an average price of 4,40 EUR. The nature of the Investment was Sell.
Schaeffler AG: A reportable insider transaction was published on 31st March 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 31st March 2025,
The Insider Transaction was made by Wagner, Uwe . The transaction toke place on 28th March 2025. The order was executed at the trading place Tradegate. . The aggregated volume was 40.092,20 EUR, based on an average price of 4,01 EUR. The nature of the Investment was Buy.
Schaeffler AG: A reportable insider transaction was published on 13th March 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 13th March 2025,
The Insider Transaction was made by Wagner, Uwe . The transaction toke place on 12th March 2025. The order was executed at the trading place Tradegate. . The aggregated volume was 100.314,80 EUR, based on an average price of 4,18 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 12th March 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 12th March 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 10th March 2025. The order was executed at the trading place Xetra. . The aggregated volume was 16.920,00 EUR, based on an average price of 1,88 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Viromed Medical AG: A reportable insider transaction was published on 7th February 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 7th February 2025,
The Insider Transaction was made by Perbandt, Uwe . The transaction toke place on 5th February 2025. The order was executed at the trading place Xetra. . The aggregated volume was 23.260,00 EUR, based on an average price of 1,93 EUR. The nature of the Investment was Buy.
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.